Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination

European Journal of Cancer

Volumn 47, Issue 13, 2011, Pages 1955-1961

  Keizman, Daniel ^a   Huang, Peng ^a   Eisenberger, Mario A ^a   Pili, Roberto ^a   Kim, Jenny J ^a   Antonarakis, Emmanuel S ^a   Hammers, Hans ^a   Carducci, Michael A ^a  

^a Bunting Blaustein Cancer Research Building ^*  (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor blockers; Metastatic renal cell carcinoma; Outcome; Sunitinib

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BILIRUBIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERFERON; SUNITINIB;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; EDEMA; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHRECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; TASTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

AGED; ANGIOGENESIS INHIBITORS; ANGIOTENSINS; CARCINOMA, RENAL CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PYRROLES; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80051889719     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.019     Document Type: Article

References (25)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. J.S. Lam, J.T. Leppert, A.S. Belldegrun, and R.A. Figlin Novel approaches in the therapy of metastatic renal cell carcinoma World J Urol 23 2005 202 212 (Pubitemid 41136043)
3. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma N Engl J Med 335 1996 865 875
4. N.K. Janzen, H.L. Kim, R.A. Figlin, and A.S. Belldegrun Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 2003 843 852 (Pubitemid 37485197)
5. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma NEJM 356 2007 115 124 (Pubitemid 46089672)
6. A. Muscella, S. Greco, M.G. Elia, C. Storelli, and S. Marsigliante Angiotensin II stimulation of Na+/K+ ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells J Endocrinol 173 2002 315 323 (Pubitemid 34552460)
7. J.A. Nadal, G.M. Scicli, L.A. Carbini, and A.G. Scicli Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-beta and PDGF-BB Am J Physiol Heart Circ Physiol 282 2002 H739 H748 (Pubitemid 34655001)
8. C.C. Chua, R.C. Hamdy, and B.H. Chua Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells Biochim Biophys Acta 1401 1998 187 194 (Pubitemid 28129101)
9. C. Pupilli, L. Lasagni, and P. Romagnani Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells J Am Soc Nephrol 10 1999 245 255 (Pubitemid 29068063)
10. E.I. Aget, J. Neo, and C. Christophi The renin-angiotensin system and malignancy Carcinogenesis 29 2008 1675 1684
11. K. Ino, K. Shibata, and H. Kajiyama Manipulating the angiotensin system-new approaches to the treatment of solid tumours Expert Opin Biol Ther 6 2006 243 255 (Pubitemid 43344744)
12. Kedika R, Patel M, Pena Sahdala HN, et al. Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps. J Clin Gastroenterol 2010 Aug 6. [Epub ahead of print].
13. J.H. Neo, C. Malcontenti-Wilson, V. Muralidharan, and C. Christophi Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases J Gastroenterol Hepatol 22 2007 577 584 (Pubitemid 46434989)
14. Q. Gong, M. Davis, G. Chipitsyna, C.J. Yeo, and H.A. Arafat Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells Pancreas 39 2010 581 594
15. V. Fendrich, N.M. Chen, and M. Neef The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer Gut 59 2010 630 637
16. S. Wilop, S. von Hobe, and M. Crysandt Impact of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy J Cancer Res Clin Oncol 135 2009 1429 1435
17. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
18. Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2010 Jul 25. [Epub ahead of print].
19. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
20. T.K. Choueiri, A. Plantade, and P. Elson Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
21. Rini BI, Cohen DP, Lu D, et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at the 2010 Genitourinary Cancers Symposium [Abstr. 312].
22. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
23. B. Escudier, J. Bellmunt, and S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
24. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2010 Nov 18. [Epub ahead of print].
25. M.E. Gore, C. Szczylik, and C. Porta Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763